DBT, BIRAC and CEPI renew cooperation agreement for vaccine development
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
Subscribe To Our Newsletter & Stay Updated